My research focuses on understanding how the brain processes reward, anxiety, and aversion, with the goal of identifying mechanisms that drive motivated behavior and contribute to substance use disorders. I am particularly interested in how specific neural systems can be targeted to develop more effective substance use disorder treatments.
Currently, a major focus of the lab is on glucagon-like peptide-1 receptor (GLP-1R) agonists such as semaglutide (Ozempic). These drugs were originally developed to treat type II diabetes and obesity. However, a growing body of literature demonstrates that GLP-1R agonists reduce craving and drug-seeking behavior and modulate brain circuits involved in aversion and anxiety during substance use. My research explores how GLP-1R agonists influence these systems to affect both the rewarding and aversive aspects of substance use and ultimately decrease relapse.
Projects in the lab aim to characterize the efficacy of these treatments in reducing nicotine and opioid withdrawal-related behaviors, examine sex differences in treatment response, and directly compare the behavioral and neural effects of different GLP-1R agonists. By studying how these drugs interact with specific brain regions involved in reward and aversion, my lab aims to inform the development of new, evidence-based treatments for substance use disorders and related neuropsychiatric conditions.
Interested in Joining the Lab?
Undergraduate student researchers explore original questions about the brain and behavior in my lab. Students can participate as research assistants, pursue independent research for course credit, and/or complete senior projects. If you’re interested in joining the lab, feel free to contact me about research opportunities.